The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Morgan Adam since 2023.
This trader's CIK number is 1964335.
At the time of last reporting, Morgan Adam was the Officer of Heron Therapeutics, Inc. /de/. (stock ticker symbol HRTX).
Also see all insider trading activities at Heron Therapeutics, Inc. /de/.
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2025 | HRTX | 1,766,546 | $2,649,819 | 0 | $0 | 0 | $0 |
2023 | HRTX | 2,486,744 | $3,406,839 | 0 | $0 | 0 | $0 |
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2024 | JSPR | 350,000 | $4,532,500 | 0 | $0 | 0 | $0 |
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2023 | ALIM | 1,401,901 | $2,383,231 | 0 | $0 | 0 | $0 |
1. Heron Therapeutics, Inc. /de/ (HRTX)
2. Jasper Therapeutics, Inc. (JSPR)
3. Alimera Sciences Inc (ALIM)
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2025-08-08 | HRTX | Buy | 1,766,546 | 1.50 | 2,649,819 |
2023-07-21 | HRTX | Buy | 2,486,744 | 1.37 | 3,406,839 |
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2024-02-08 | JSPR | Buy | 350,000 | 12.95 | 4,532,500 |
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2023-05-17 | ALIM | Buy | 1,401,901 | 1.70 | 2,383,231 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Morgan Adam (Officer of Heron Therapeutics, Inc. /de/ at the time of this reporting) see the Securities and Exchange Commission (SEC) website.